Screener
Collegium Pharmaceutical, Inc. COLL Segment — Product revenues, net
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Collegium Pharmaceutical, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Collegium Pharmaceutical, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:34 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053851
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Product revenues, net | $199,878 | $188,000 | $393,398 | $365,757 |
| Cost of product revenues (excluding intangible asset amortization) | 26,633 | 24,143 | 47,434 | 49,103 |
| Intangible asset amortization | 62,953 | 55,473 | 118,426 | 110,946 |
| Commercial expenses | 46,403 | 44,115 | 93,760 | 84,908 |
| Corporate expenses | 12,163 | 9,801 | 26,703 | 23,090 |
| Medical expenses | 7,899 | 7,832 | 15,047 | 15,865 |
| Technical operations expenses | 165 | 136 | 415 | 234 |
| Stock-based compensation expense | 14,484 | 10,818 | 25,364 | 22,342 |
Item 1. Condensed Consolidated Financial Statements (Unaudited).
FAQ
- What is Collegium Pharmaceutical, Inc.'s segment — product revenues, net?
- Collegium Pharmaceutical, Inc. (COLL) reported segment — product revenues, net of $199.88M in Q2 2026.
- How has Collegium Pharmaceutical, Inc.'s segment — product revenues, net changed year-over-year?
- Collegium Pharmaceutical, Inc.'s segment — product revenues, net increased by 6.3% year-over-year, from $188M to $199.88M.
- What is the long-term trend for Collegium Pharmaceutical, Inc.'s segment — product revenues, net?
- Over 3 years (2022 to 2025), Collegium Pharmaceutical, Inc.'s segment — product revenues, net has grown at a 18.9% compound annual growth rate (CAGR), from $463.93M to $780.57M.
- What does segment — product revenues, net mean?
- Represents the total revenue generated from the sale of pharmaceutical products after accounting for returns, rebates, and other sales deductions. This is the primary top-line metric for evaluating the market demand and commercial success of the company's drug portfolio.
Ask your AI about Collegium Pharmaceutical, Inc.'s segment — product revenues, net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude